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Aortic stenosis (AS) is a result of a progressive 
increase in calcium deposition within the aortic 
valve, leading to increased stiffness and pro-
gressive narrowing of the valve. Whilst in the 
past the pathogenesis of AS was thought to be 
due to “wear and tear”, it is now recognized that 
it is a complex process, involving inflammatory 
infiltration, endothelial disruption and dysfunc-
tion, fibrosis and calcification. Aortic sclerosis 
(ASc), the earliest stage of this process, is char-
acterized by abnormal valve morphology in the 
absence of haemodynamically significant ob-
struction of valve orifice [1].  
 
Even the ASc stage of the disease is associated 
with the considerable cardiovascular morbidity 
and mortality [2, 3]. Early studies identified a 
number of clinical factors associated with the 
presence of calcific aortic valve disease (not 
always distinguishing between stenosis and 
sclerosis). These include age, body mass index, 
smoking, hypertension, dyslipidaemia, diabetes 
and lipoprotein (a) levels [4-9]. In the more re-
cent, and much larger, Cardiovascular Health 
Study [1] the risk factors independently associ-
ated with calcific aortic valve disease were age, 
male gender, lipoprotein (a) levels, height, hy-
pertension, smoking and LDL levels, all of which 
remained significant when only ASc was consid-
ered. We have demonstrated that reduced 
platelet responsiveness to nitric oxide, ad-
vanced age and low BMI, but not conventional 
coronary risk factors, are independent corre-
lates of presence of ASc in a randomly selected 
ageing Western population cohort [10]. 
 
Thus the investigations have been directed to-
wards better understanding of pathogenesis of 
ASc, with the ultimate objective of developing 
strategies to retard its progression. Whilst a 
number of studies, mainly epidemiological, have 
examined the factors associated with the pres-
ence of ASc, very few have looked at the deter-
minants of progression of ASc. Despite similari-
ties in clinical factors associated with AS and 
atherogenesis, factors underlying progression 
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are not identical. The putative risk factor that 
has attracted the most controversy is that of 
dyslipidemia. There is considerable evidence for 
the involvement (as distinct from pivotal impor-
tance) of cholesterol and other lipoproteins in 
pathogenesis of AS and ASc (reviewed by [11]), 
although not every study reported such an asso-
ciation [12-14]; yet none of the prospective, 
randomized, place-controlled trials to retard the 
progression of AS via cholesterol lowering have 
been successful [15-17]. 
 
Presence of inflammatory activation and infiltra-
tion has been demonstrated in AS/ASc lesions 
histologically [18, 19], yet the clinical relevance 
of the markers of inflammation has only been 
assessed in one prospective study to date. In a 
follow-up of the Cardiovascular Health Study, 
involving more than 5600 subjects, of whom 
1610 had ASc and 94 had AS, the authors 
found that increasing age, male gender, African-
American ethnicity and increases in low-density 
lipoprotein cholesterol levels were significant 
predictors of new development of AS and ASc 
(combined). Similarly, progression from ASc to 
AS was significantly associated with male gen-
der, advancing age and African-American ethnic-
ity. CRP levels were not associated with devel-
opment or progression of calcific aortic valve 
disease [20].  
 
Previous studies have widely reported the asso-
ciation between increasing BMI and systemic 
inflammatory activation (reviewed by [21]). Yet 
we have found a “paradoxical” association be-
tween low BMI and reduced risk of presence of 
ASc [10]. In fact this “paradoxical” relationship 
has also been documented as regards survival 
in patients with chronic kidney disease [22], 
where it is thought to be that malnourishment 
leads to even greater atherogenic risk than obe-
sity. 
 
Nitric oxide (NO) has been shown to exert a 
wide variety of physiologic effects in cardiovas-
cular system and specifically related to aortic 
valve structure and function. NO has important 
anti-inflammatory and vasodilator properties; it 
limits calcification in cell culture of aortic valve 
fibroblasts [23] and impairment of NO respon-
siveness has been demonstrated in patients 
with AS and ASc [10, 24]. Impairment of platelet 
NO responsiveness in itself has been shown to 
be an independent marker of adverse cardio-
vascular events [25].  
In the current investigation, we have therefore 
sought to resolve the paradox inherent in the 
inverse relationship between BMI and risk of 
ASc, given that increasing BMI is associated 
with systemic inflammatory activation, and yet 
with reduced prevalence of ASc [10]. We hy-
pothesised that the BMI : hsCRP relationship 
would be attenuated or reversed in the pres-
ence of ASc. In view of the association of plate-
let NO resistance with prevalence of ASc [10], 
but also with obesity [26], we also evaluated 
possible dissociation of the BMI : platelet NO 
responsiveness relationship in ASc. 
 




The study cohort (n=253) represented a subset 
of the North Western Adelaide Health Study 
aged 51 to 77 years, who had not undergone 
aortic valve surgery. This cohort of ambulant but 
aging individuals was initially evaluated to iden-
tify risk factors for aortic valve calcification [10]. 
Subject characteristics are summarized in Table 
1. All volunteers gave informed consent before 
the study. The study was approved by the Ethics 





Complete transthoracic echocardiographic stud-
ies were performed in all subjects with a com-
mercially available system (Vivid 5 [GE Vingmed, 
Horten, Norway], with a 2.5 MHz phased array 
probe). M-mode and 2-dimensional (2D) echo-
cardiograms with Doppler analysis were ob-
tained for all subjects. Mean and peak pressure 
gradients across the aortic valve were calcu-
lated with the modified Bernoulli equation, with 
continuous-wave Doppler recordings from the 
highest velocity available from any view. The 
aortic valve area was computed with the conti-
nuity equation with standard methods. Valve 
morphology was categorized on the basis of 
visual assessment, as previously described 
[27]. 
 
Ultrasound backscatter data analysis 
 
Aortic valve backscatter values (AVBS) were 
obtained for all subjects with methods as previ-
ously published [28]. Briefly, 2D ultrasonic back-
scatter images of the aortic valves were ob-
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tained from standard parasternal long-axis 
views over 3 cardiac cycles with a zoom of 8 cm. 
Three consecutive scans were acquired for each 
study subject. Backscatter values from the 
blood pool in the LV outflow tract and aortic root 
were used as reference values. Calibrated back-
scatter values were obtained by subtracting the 
average blood pool value from the averaged 
backscatter values obtained from the aortic 
valves. Subjects with AVBS values ≥ 16dB were 
considered to have ASc in keeping with previ-




Lipid profile, high-sensitivity C-reactive protein 
(hs-CRP), serum creatinine, calcium, phosphate, 
and 1,25 dihydroxy cholecalciferol (vitamin D 
levels) were measured by a 125I radioimmuno-
assay (Immunodiagnostic Systems Ltd., Bolden, 
United Kingdom). Creatinine clearance (CrCl) 
was calculated according to the Cockcroft-Gault 
equation and indexed for body surface area 




All data are expressed as mean ± SD unless 
otherwise stated. Normal distribution was 
tested for all continuous variables, and skewed 
data were normalized either by log or square 
root transformation. Comparisons between 
groups for normally distributed data were per-
formed with nonpaired t tests and, comparisons 
for nonparametric data were made with the 
Mann-Whitney test. Correlations between trans-
formed, continuous nonparametric data were 
made with linear regression. The impact of the 
presence or absence of ASc on the BMI : hs-CRP 
and BMI : platelet NO responsiveness relation-
ships were tested by ANCOVA. All analyses were 
performed using GraphPad Prism 5 software 
(GraphPad, USA), and a p value of less than .05 






Baseline patient characteristics are shown in 
Table 1. There was a high proportion of obese 
subjects (31% of subjects had BMI ≥ 30), multi-
ple coronary risk factors were frequently pre-
sent, and there was extensive therapy with stat-
ins and angiotensin-converting enzyme inhibi-
tor/angiotensin receptor blockers. ASc was pre-
sent in 19% (n=49) of subjects based on AVBS 
scores. Subjects with ASc were generally older 




Biochemical findings are summarized in Table 
2. Plasma cholesterol concentrations were ele-
vated beyond normal (> 5.5 mmol/l) in 26.4% of 
subjects at entry. In general, renal function was 
well-preserved: there were no patients on dialy-
sis, with only 2 subjects with CrCl < 30 ml/
min/1.73 m2. Comparisons between subjects 
with and without ASc revealed that CrCl was 
significantly greater in subjects without ASc. 
Levels of hs-CRP were not significantly different 
Table 1. Patient characteristics: clinical data 
Characteristic 
No ASc 
(AVBS score < 16 dB) (n=204) 
ASc 
(AVBS score ≥ 16 dB) (n=49) p value 
Age (mean ± SD) (yrs) 63 ± 6.0 64.9 ± 9 0.045 
BMI (kg/m2) 28.5 ± 5.1 26.7 ± 4.2 0.019 
Gender (% male) 42% 49% 0.372 
History of hypercholesterolemia 61.8% 53.1% 0.565 
Statin therapy 30.5% 38.8% 0.268 
Previous angina/MI 11.9% 20.4% 0.114 
ACEI/AIIRB therapy 34.8% 25% 0.193 
Hypertension 44.1% 32.7% 0.146 
Family history of CVD 51% 57.1% 0.439 
Smoking 14.8% 12.2% 0.649 
Diabetes mellitus 10.8% 10.2% 0.898 
BMI – Body mass index; MI – Myocardial infarction; ACEI – Angiotensin converting enzyme inhibitor; AIIRB – Angiotensin II receptor 
blocker; CVD – Cardiovascular disease. 
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for those with and without ASc.  
 
BMI vs hs-CRP: impact of ASc 
 
In the entire cohort there was a direct correla-
tion between BMI and hs-CRP (Figure 1A; 
r=0.42; p<0.0001). When this relationship was 
considered separately for subjects with and 
without ASc (Figure 1B), the relationship was 
significant for each cohort [ASc: r=0.42, 
p=0.003; no ASc: r=0.43, p<0.0001], but the 
difference between gradients was not statisti-
cally significant (ANCOVA: p for interaction = 
0.96). 
 
BMI vs platelet NO responsiveness: impact of 
ASc 
 
Surprisingly, there was no significant relation-
ship between BMI and platelet responsiveness 
to NO in the entire population (Figure 2A). When 
subjects with and without ASc were considered 
separately (Figure 2B), there was a trend 
(ANCOVA: p=0.08) for subjects with ASc to have 
greater reductions in NO responsiveness with 




This study demonstrates that the presence of 
ASc is not associated with significant perturba-
tion of the BMI : hs-CRP relationship. Further-
more, in this population obesity was not signifi-
cantly associated with platelet NO resistance, 
nor did a different relationship emerge in the 
presence of ASc. 
 
The rationale for this investigation is the emerg-
ing evidence for inflammatory activation and 
impairment of NO signaling cascade in subjects 
with ASc as discussed below. 
 
ASc is associated with intra-valvular inflamma-
tory activation 
 
This includes evidence of local secretion of an-
giotensin II [29], presence of inflammatory infil-
Table 2. Patient characteristics: baseline biochemical data (expressed as mean ± standard deviation) 
Parameter 
No ASc 
(AVBS score < 16 dB) 
ASc 
(AVBS score ≥ 16 dB) 
p value 
hs-CRP (mmol/L) 3.5 ± 3.6 4 ± 5.6 0.576 
% platelet responsiveness to SNP 34.8 ± 27.5 26.6 ± 25.4 0.084 
Total cholesterol (mmol/L) 5 ± 1 4.9 ± 1 0.774 
LDL (mmol/L) 2.9 ± 0.9 2.8 ± 0.7 0.549 
HDL (mmol/L) 1.3 ± 0.3 1.4 ± 0.4 0.126 
Calcium (mmol/L) 2.2 ± 0.1 2.2 ± 0.1 0.7 
Phosphate (mmol/L) 1 ± 0.2 1 ± 0.2 0.129 
CrCL (indexed for BSA) 
(ml/min/1.73m2) 84.2 ±22.7 76 ± 20 0.022 
hs-CRP – high sensitivity C-reactive protein; SNP – sodium nitroprusside; LDL – low density lipoprotein; HDL – high density lipopro-
tein; CrCL – creatinine clearance. 
 
Figure 1. A. Correlation of BMI with normalized plasma hs-
CRP concentrations for the entire cohort (r=0.42; 
p<0.0001); B. ANCOVA: relationship between BMI and 
normalized plasma hs-CRP concentrations according to 
presence/absence of ASc (p=0.96) 
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trates [18, 19], and identification of local forma-
tion of reactive oxygen species such as hydro-
gen peroxide [30]. Furthermore, we have dem-
onstrated in an animal model that ASc/mild AS 
is associated with increased intra-valvular con-
tent of thoiredoxin interacting protein [31], a 
key regulator of inflammasome activation [32]. 
 
ASc is associated with impaired NO generation/
effect systemically 
 
ASc is associated with endothelial dysfunction 
in humans [33]; in a rabbit model of ASc/mild 
AS there is also a relative increase in asymmet-
ric dimethylarginine levels [31], a marker and 
mediator of endothelial dysfunction [34]. Fur-
thermore, on multivariate analysis, 
presence of ASc is associated with 
impaired platelet NO responsive-
ness in humans [10]. Therefore it 
has been postulated that impaired 
NO generation/effect might (a) re-
sult from increased oxidative stress 
in ASc, (b) account for the increased 
risk of cardiovascular events in ASc 
patients [3]. However, ASc (and in-
deed AS) occurs predominantly in 
lean individuals, with a negative 
relationship on multivariate analysis 
between BMI and AVBS [10], a 
measure of valve echogenicity [28]. 
This relationship is puzzling, as in-
creasing BMI is associated with sys-
temic inflammatory activation, 
largely reflecting underlying 
changes in adipocytes [35]. In order 
to reconcile these superficially para-
doxical findings, we hypothesized 
that the BMI : hs-CRP and BMI : 
platelet NO responsiveness relation-
ships would be “reversed” in the 
presence of ASc. 
 
In the case of hs-CRP, there was 
non-significant attenuation of the 
BMI : hs-CRP relationship in the 
presence of ASc (Figure 1B), such 
that these was no significant in-
crease in hs-CRP with BMI in-
creases in ASc subjects. It is possi-
ble that the lack of significant differ-
ences reflects Type II error. How-
ever, it is more likely that the result 
suggests that ASc per se is not as-
sociated with marked systemic in-
flammatory activation, at least as measured by 
hs-CRP. 
 
The results with platelet NO responsiveness are 
surprising, in view of the previous data of An-
fossi et al [26], who demonstrated NO resis-
tance in an obese insulin-resistant cohort. While 
insulin responsiveness was not measured, there 
was no evidence of a relationship between BMI 
and platelet NO responsiveness overall. In sub-
jects with ASc, there was a borderline significant 
(p=0.08) decline in platelet NO responsiveness 
with increasing BMI. Thus, there was no evi-
dence to suggest that in subjects with ASc NO 
resistance might emerge in lean individuals. 
These data therefore suggest that the bases of 
Figure 2. A. Correlation of BMI with normalized platelet SNP respon-
siveness for the entire cohort (p=0.6); B. ANCOVA: relationship be-
tween BMI and normalized platelet SNP responsiveness according to 
presence/absence of ASc (F= 3.1; p=0.08). 
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platelet NO resistance and systemic inflamma-




The inverse relationship between obesity and 
prevalence of ASc does not appear to be re-
flected in substantial alteration of obesity-
related inflammatory activation or of BMI-
selective disturbances of platelet NO respon-
siveness. Although ASc is clearly associated 
with intra-valvular inflammatory activation, 
those data suggest that it is not the product of a 
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